Bladder Cancer Clinical Trial

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

Summary

The purpose of this study is to investigate if blue light cystoscopy with Cysview improves detection of tumors in patients with bladder cancer during surveillance cystoscopy, using the KARL STORZ D-Light C PDD Flexible Videoscope System. Another purpose is to investigate if Cysview and blue light is safe and effective when used repeatedly.

View Eligibility Criteria

Eligibility Criteria

Patients with bladder cancer in follow-up for tumor recurrence (Note: Patients must be included only at the first surveillance cystoscopy after a histologically confirmed tumor. The histologically confirmed tumor could either be from a TURB or from a surveillance cystoscopy where a biopsy was taken and a tumor was confirmed by histology)

History of one or more of the following:

Multiple tumors
Recurrent tumors
High grade tumor(s)

Exclusion Criteria:

Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed resulting in significant amounts of blood in the urine, which may visually limit cystoscopy. Where the haematuria is light, the patient should not be excluded, if in the investigator's opinion, rinsing and/or electro-cautery during cystoscopy will alleviate the haematuria limitations to cystoscopy)
Patients who cannot undergo in-office or operating room cystoscopy (Note: Training patients are eligible even if they cannot undergo operating room cystoscopy)
Patients who have received Bacillus Calmette-Guérin (BCG) immunotherapy or intravesical chemotherapy within the past 6 weeks prior to the procedure
Porphyria
Known allergy to hexaminolevulinate hydrochloride or a similar compound
Pregnancy or breast-feeding (all women of child-bearing potential must document a negative urine pregnancy test before study inclusion and use adequate contraception during the study
Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days
Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
Patients that the investigator believes are unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of participating in the clinical study, uncooperative attitude or unlikelihood of completing the study

Study is for people with:

Bladder Cancer

Phase:

Phase 3

Estimated Enrollment:

304

Study ID:

NCT02560584

Recruitment Status:

Completed

Sponsor:

Photocure

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

USC Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States
University of Chicago Medical Center
Chicago Illinois, 60637, United States
University of Iowa
Iowa City Iowa, 52242, United States
Johns Hopkins University
Baltimore Maryland, 21205, United States
University of Minnesota
Minneapolis Minnesota, 55455, United States
Montefiore Medical Center
Bronx New York, 10461, United States
NYU Langone Urology Associates
New York New York, 10016, United States
Columbia University Medical Center
New York New York, 10032, United States
University of North Carolina, Department of Urology
Chapel Hill North Carolina, 27599, United States
Ohio State University The James Cancer Hospital
Columbus Ohio, 43210, United States
University of Oklahoma-Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States
Thomas Jefferson University
Philadelphia Pennsylvania, 10197, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
UT Southwestern Medical Center
Dallas Texas, 75390, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Michael E. DeBakey VA Medical Center
Houston Texas, 77030, United States
University of Wisconsin
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 3

Estimated Enrollment:

304

Study ID:

NCT02560584

Recruitment Status:

Completed

Sponsor:


Photocure

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider